RxDoctor Payments Data

Randall Bjork, MD

Neurology · Mishawaka, INNPI 1265434112

Payments from drug & device makers

$16,419in general payments, 2019–2025

Across 529 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • AstraZeneca$1K
  • Bristol Myers Squibb$785
  • Johnson & Johnson$781
  • AbbVie$725
  • Amgen$639
  • plus $11K from 53 others

What the payments were for

  • Food & beverage$16,416100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.64$1,554
AstraZeneca(2 entities)32$1,249
Bristol Myers Squibb35$785
Johnson & Johnson(2 entities)14$781
AbbVie(2 entities)15$725
Amgen(2 entities)21$639
Neurocrine Biosciences, Inc.18$631
Argenx US, Inc.17$610
Jazz Pharmaceuticals Inc.10$590
SK Life Science, Inc.20$559
Biogen27$545
EMD Serono, Inc.16$519
Banner Life Sciences, LLC14$433
Acadia Pharmaceuticals Inc8$419
UCB, Inc.17$409
Eisai Inc.9$402
E.r. Squibb & Sons, L.L.C.3$361
Catalyst Pharmaceuticals, Inc.8$336
Biohaven Pharmaceuticals, Inc.4$319
Biohaven Pharmaceutical Holding Company Ltd.7$317
TG Therapeutics, Inc.9$308
Cala Health, Inc.6$269
Genentech, Inc.2$257
Otsuka America Pharmaceutical, Inc.8$251
Lilly USA, LLC15$248
Mallinckrodt Hospital Products Inc.10$232
Neurelis, Inc.7$227
Lundbeck LLC5$213
MDD US Operations, LLC8$198
Takeda Pharmaceuticals U.S.A., Inc.4$189
Novartis12$182
Amneal Pharmaceuticals LLC9$180
Sanofi7$154
Livanova USA, Inc.9$138
Vanda Pharmaceuticals Inc.4$135
Boston Scientific1$121
Genentech USA, Inc.7$116
Acorda Therapeutics, Inc6$79
Pfizer5$78
Ipsen Biopharmaceuticals, Inc3$58
Adamas Pharmaceuticals, Inc.3$53
Greenwich Biosciences, Inc.3$49
Axsome Therapeutics, Inc.2$48
CSL Behring3$44
Tanabe Pharma America, Inc.2$42
Cycle Pharmaceuticals Inc2$42
Grifols USA, LLC2$38
Scilex Pharmaceuticals Inc.2$33
Sunovion Pharmaceuticals Inc.3$29
Avanir Pharmaceuticals, Inc.2$29
Tersera Therapeutics LLC1$27
Alnylam Pharmaceuticals Inc.1$25
Octapharma USA, Inc.1$23
Impel Pharmaceuticals Inc.1$23
C2n Diagnostics, LLC1$23
Springworks Therapeutics, Inc.1$22
Amylyx Pharmaceuticals, Inc.1$22
Sumitomo Pharma America, Inc.1$18
Upsher-smith Laboratories LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,419 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$64,182
Medicare patients
344
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$168,351
Nurtec OdtRimegepant Sulfate96$114,334
IngrezzaValbenazine Tosylate13$103,507
CopaxoneGlatiramer Acetate13$75,857
XcopriCenobamate40$42,904
Glatiramer Acetate12$36,317
OngentysOpicapone34$34,655
QuliptaAtogepant26$33,772
Aimovig AutoinjectorErenumab-Aooe19$20,862
Emgality PenGalcanezumab-Gnlm23$19,833
FycompaPerampanel17$19,090
UbrelvyUbrogepant11$11,170
Lacosamide77$8,969
Levetiracetam156$7,518
Memantine Hcl193$5,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$1,554$244,20826 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$631$138,16247 claims
PfizerNurtec Odt$78$114,33496 claims
AbbVieQulipta, Ubrelvy$725$44,94237 claims
SK Life Science, Inc.Xcopri$559$42,90440 claims
Eisai Inc.Fycompa$402$19,09017 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$180$3,00828 claims
Upsher-smith Laboratories LLCTopiramate$14$38548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Indiana.

Other neurology in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →